Search

Displaying results 3901 - 3910 of 4188 in total
  1. Drug

    CP-39,332

    go.drugbank.com/drugs/DB09193
    Experimental

    However, none of the members of this stereoisomers has been marketed.

  2. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It has never been approved for use in the U.S. or Canada.

  3. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    The ability of P188 in attenuating membrane damage and cell injury has been demonstrated in a variety of _in vivo_ and _in vitro_ models [A27218].

  4. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It has been investigated for use in the treatment of arthritis and as a neuroprotective agent in aneurysmal subarachnoid hemorrhage.

  5. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252340] New thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and [reteplase], have also been developed.

  6. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    Bile acid sequestrants like colestipol have been in use since the 1970s.

  7. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard

  8. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies.

  9. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    It acts intracellularly on the MAPK signaling pathway by activating ERK2.

  10. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.